Who founded Massive Bio?

Massive Bio was founded by Selin Kurnaz, Arturo Loaiza-Bonilla in 2015.

Who are Massive Bio's investors?

Massive Bio's investors include 500 Emerging Europe, 500 Global, Revo Capital, e2vc.

How much funding has Massive Bio raised?

Massive Bio has disclosed $5.1M raised across 2 of its 3 known rounds.

Where is Massive Bio headquartered?

Massive Bio is headquartered in New York, US.

Massive Bio

New York, US · Founded 2015 · Delaware corporation · 6 known investors

Find your way into Massive Bio

737 people in our graph share verified history with the Massive Bio team — schools, employers, funds. One of them is your warm intro.

Viswa Sankaranarayananunlockedknows Selin Kurnaz · together at The University of Texas at Austin (overlapped)

×2knows the team · via University of Pennsylvania

knows the team · via The University of Texas at Austin

×2knows the team · via OpenAI

knows the team · via Penn Medicine, University of Pennsylvania Health System

×4knows the team · via Boğaziçi University

Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.

AI & Machine Learning Biotech Digital Health Healthtech

Founders & leadership

Massive Bio was founded in 2015 by Selin Kurnaz and Arturo Loaiza-Bonilla.

Selin Kurnaz in 𝕏Co-Founder and CEOSelin Kurnaz holds engineering degrees from the University of Michigan and spent 10 years in management consulting before joining EY's Private Equity Value Creation group, where she worked on healthcare investment decisions; she founded Massive Bio to expand access to clinical trials for cancer patients globally.

Arturo Loaiza-Bonilla in 𝕏Co-Founder & Chief Medical  AI Officer (CMAIO)Dr. Arturo Loaiza-Bonilla is Co-Founder and Chief Medical AI Officer at Massive Bio, an AI platform that matches cancer patients with clinical trials. He also serves as Systemwide Chief of Hematology and Medical Oncology at St. Luke's University Health Network and holds roles with organizations including ASCO, Meta, OpenAI, and NeurIPS.

Investors · 6

500 Emerging EuropeAmsterdam

500 GlobalSan Francisco · $150K

Revo CapitalIstanbul · $250K – $5M

e2vcreported

Also in the syndicate · 2

Cavendish Impact Foundation (CIF)ImpactAssets

Funding

SEC filings, press & company announcements

$5.1M disclosed across 2 of 3 rounds · 2019–2022

$2.6MraisedNov 2020 · 2 sources
Revo Capital (lead), Cavendish Impact Foundation (CIF), ImpactAssets
Source ↗

▶$2.5MraisedMay 2019 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Selin KurnazExecutive Officer
Arturo Loaiza-BonillaDirector

Offering amount: $5.5M
Amount sold: $2.5M
Minimum investment: $500K
First sale: Apr 2019
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Osmosis27914 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Medscape27407 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Massive Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2020	$399.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Massive Bio Makes Inaugural Strategic Investment in Rivvi to Build an End-to-End AI Engagement Infrastructure for Healthcare - AOLaol.com · Aug 2026

Massive Bio Raises $9 Million To Scale Growth and Fuel Global Expansion of AI-Enabled Oncology Clinical Trial Platformmassivebio.com · Jun 2022

Massive Bio Raises $2.6 Million for Oncology Clinical Trial Platform - Mercom Capital Groupmercomcapital.com · Nov 2020

Massive Bio Secures Additional $2.6 Million Financing Round Led by Revo Capital and Tops its Total Raise to $6.6 Million - Boston Real Estate Timesbostonrealestatetimes.com · Nov 2020

Frequently asked questions

What does Massive Bio do?: Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Who founded Massive Bio?: Massive Bio was founded by Selin Kurnaz, Arturo Loaiza-Bonilla in 2015.
Who are Massive Bio's investors?: Massive Bio's investors include 500 Emerging Europe, 500 Global, Revo Capital, e2vc.
How much funding has Massive Bio raised?: Massive Bio has disclosed $5.1M raised across 2 of its 3 known rounds.
Where is Massive Bio headquartered?: Massive Bio is headquartered in New York, US.